Primary Prevention of Cardiovascular Disease in People With Dysglycemia

被引:36
作者
Bianchi, Cristina [1 ]
Miccoli, Roberto [1 ]
Penno, Giuseppe [1 ]
Del Prato, Stefano [1 ]
机构
[1] Univ Pisa, Sect Diabet & Metab Dis, Dept Endocrinol & Metab, Pisa, Italy
关键词
D O I
10.2337/dc08-s256
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Cardiovascular disease accounts for a great majority of deaths in patients with type 2 diabetes. According to the World Health Organization, the prevalence of cardiovascular disease in diabetic patients ranges from 26 to 36%. Fatality rate after myocardial infarction is greater in diabetic patients, and overall prognosis after coronary heart disease is worse. Based on these observations, it has been proposed that diabetes should be considered as a coronary heart disease risk equivalent. if that is the case, prevention of diabetes and early, intervention should be pursued. This view is supported by the notion that cardiovascular risk is already increased in people with impaired glucose tolerance. Moreover, higher-than-optimum blood glucose is a major cause of cardiovascular mortality in most world regions Of the world. Whether dysglycemia is a marker for a more complex Metabolic condition or may directly contribute to excess cardiovascular risk is still a matter of debate, However, experimental work has shown how increased glucose level can trigger multiple mechanisms of susceptibility to atherosclerosis, and diabetes prevention trials have indicated that along with reduction of the rate of conversion toward diabetes, significant improvement in cardiovascular risk factors occurs. Moreover, in the STOP-NIDDM trial, targeting postprandial glucose was associated With reduction in new cases of hypertension, myocardial infarction, and any cardiovascular events. In conclusion, dysglycemia should be included in the list of established cardiovascular risk factors and early treatment introduced in the attempt to improve cardiovascular morbidity and mortality.
引用
收藏
页码:S208 / S214
页数:7
相关论文
共 62 条
[31]   Glycated haemoglobin, diabetes, and mortality in men in Norfolk cohort of European Prospective Investigation of Cancer and Nutrition (EPIC-Norfolk) [J].
Khaw, KT ;
Wareham, N ;
Luben, R ;
Bingham, S ;
Oakes, S ;
Welch, A ;
Day, N .
BMJ-BRITISH MEDICAL JOURNAL, 2001, 322 (7277) :15-18B
[32]   Glucose tolerance and mortality, including a substudy of tolbutamide treatment [J].
Knowler, WC ;
Sartor, G ;
Melander, A ;
Schersten, B .
DIABETOLOGIA, 1997, 40 (06) :680-686
[33]  
Knowler WC, 2002, NEW ENGL J MED, V346, P393, DOI 10.1056/NEJMoa012512
[35]  
Lawes CMM, 2004, DIABETES CARE, V27, P2836
[36]   Activation of oxidative stress by acute glucose fluctuations compared with sustained chronic Hyperglycemia in patients with type 2 diabetes [J].
Monnier, L ;
Mas, E ;
Ginet, C ;
Michel, F ;
Villon, L ;
Cristol, JP ;
Colette, C .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2006, 295 (14) :1681-1687
[37]   Relationship between HbA1c level and peripheral arterial disease [J].
Muntner, P ;
Wildman, RP ;
Reynolds, K ;
DeSalvo, KB ;
Chen, J ;
Fonseca, V .
DIABETES CARE, 2005, 28 (08) :1981-1987
[38]  
Nathan DM, 2003, NEW ENGL J MED, V348, P761
[39]   Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes [J].
Nathan, DM ;
Cleary, PA ;
Backlund, JYC ;
Genuth, SM ;
Lachin, JM ;
Orchard, TJ ;
Raskin, P ;
Zinman, B .
NEW ENGLAND JOURNAL OF MEDICINE, 2005, 353 (25) :2643-2653
[40]   INTENSIVE INSULIN THERAPY PREVENTS THE PROGRESSION OF DIABETIC MICROVASCULAR COMPLICATIONS IN JAPANESE PATIENTS WITH NON-INSULIN-DEPENDENT DIABETES-MELLITUS - A RANDOMIZED PROSPECTIVE 6-YEAR STUDY [J].
OHKUBO, Y ;
KISHIKAWA, H ;
ARAKI, E ;
MIYATA, T ;
ISAMI, S ;
MOTOYOSHI, S ;
KOJIMA, Y ;
FURUYOSHI, N ;
SHICHIRI, M .
DIABETES RESEARCH AND CLINICAL PRACTICE, 1995, 28 (02) :103-117